A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Lianchun Xiao, Guillermo Garcia-Manero, William Plunkett, Varsha Gandhi, Koji Sasaki, Naveen Pemmaraju, Naval G. Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Zeev Estrov, Tapan M. Kadia, William G. Wierda, Courtney D. DiNardo, Mark Brandt, Susan M. O’BrienJorge E. Cortes, Elias Jabbour

Research output: Contribution to journalArticle

Abstract

The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n=48) or FIA (n=33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p=.50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p=.48), and the median overall survival was 6.3 and 4.7 months, respectively (p=.28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.

Original languageEnglish (US)
Pages (from-to)813-820
Number of pages8
JournalLeukemia and Lymphoma
Volume59
Issue number4
DOIs
StatePublished - Jul 19 2018
Externally publishedYes

Fingerprint

Idarubicin
Cytarabine
Acute Myeloid Leukemia
Purine Nucleosides
Random Allocation
Disease-Free Survival
Blood Platelets
Survival Rate
Survival
Mortality
clofarabine
fludarabine
Therapeutics

Keywords

  • Acute myeloid leukemia
  • Clofarabine
  • Fludarabine
  • Purine nucleoside analogues
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. / Short, Nicholas J.; Kantarjian, Hagop; Ravandi, Farhad; Huang, Xuelin; Xiao, Lianchun; Garcia-Manero, Guillermo; Plunkett, William; Gandhi, Varsha; Sasaki, Koji; Pemmaraju, Naveen; Daver, Naval G.; Borthakur, Gautam; Jain, Nitin; Konopleva, Marina; Estrov, Zeev; Kadia, Tapan M.; Wierda, William G.; DiNardo, Courtney D.; Brandt, Mark; O’Brien, Susan M.; Cortes, Jorge E.; Jabbour, Elias.

In: Leukemia and Lymphoma, Vol. 59, No. 4, 19.07.2018, p. 813-820.

Research output: Contribution to journalArticle

Short, NJ, Kantarjian, H, Ravandi, F, Huang, X, Xiao, L, Garcia-Manero, G, Plunkett, W, Gandhi, V, Sasaki, K, Pemmaraju, N, Daver, NG, Borthakur, G, Jain, N, Konopleva, M, Estrov, Z, Kadia, TM, Wierda, WG, DiNardo, CD, Brandt, M, O’Brien, SM, Cortes, JE & Jabbour, E 2018, 'A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia', Leukemia and Lymphoma, vol. 59, no. 4, pp. 813-820. https://doi.org/10.1080/10428194.2017.1349907
Short, Nicholas J. ; Kantarjian, Hagop ; Ravandi, Farhad ; Huang, Xuelin ; Xiao, Lianchun ; Garcia-Manero, Guillermo ; Plunkett, William ; Gandhi, Varsha ; Sasaki, Koji ; Pemmaraju, Naveen ; Daver, Naval G. ; Borthakur, Gautam ; Jain, Nitin ; Konopleva, Marina ; Estrov, Zeev ; Kadia, Tapan M. ; Wierda, William G. ; DiNardo, Courtney D. ; Brandt, Mark ; O’Brien, Susan M. ; Cortes, Jorge E. ; Jabbour, Elias. / A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 4. pp. 813-820.
@article{2eb4f64cd7774d06adc20eb2bc307814,
title = "A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia",
abstract = "The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n=48) or FIA (n=33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38{\%} versus 30{\%}, respectively; p=.50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p=.48), and the median overall survival was 6.3 and 4.7 months, respectively (p=.28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.",
keywords = "Acute myeloid leukemia, Clofarabine, Fludarabine, Purine nucleoside analogues, Refractory, Relapsed",
author = "Short, {Nicholas J.} and Hagop Kantarjian and Farhad Ravandi and Xuelin Huang and Lianchun Xiao and Guillermo Garcia-Manero and William Plunkett and Varsha Gandhi and Koji Sasaki and Naveen Pemmaraju and Daver, {Naval G.} and Gautam Borthakur and Nitin Jain and Marina Konopleva and Zeev Estrov and Kadia, {Tapan M.} and Wierda, {William G.} and DiNardo, {Courtney D.} and Mark Brandt and O’Brien, {Susan M.} and Cortes, {Jorge E.} and Elias Jabbour",
year = "2018",
month = "7",
day = "19",
doi = "10.1080/10428194.2017.1349907",
language = "English (US)",
volume = "59",
pages = "813--820",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

AU - Short, Nicholas J.

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

AU - Huang, Xuelin

AU - Xiao, Lianchun

AU - Garcia-Manero, Guillermo

AU - Plunkett, William

AU - Gandhi, Varsha

AU - Sasaki, Koji

AU - Pemmaraju, Naveen

AU - Daver, Naval G.

AU - Borthakur, Gautam

AU - Jain, Nitin

AU - Konopleva, Marina

AU - Estrov, Zeev

AU - Kadia, Tapan M.

AU - Wierda, William G.

AU - DiNardo, Courtney D.

AU - Brandt, Mark

AU - O’Brien, Susan M.

AU - Cortes, Jorge E.

AU - Jabbour, Elias

PY - 2018/7/19

Y1 - 2018/7/19

N2 - The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n=48) or FIA (n=33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p=.50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p=.48), and the median overall survival was 6.3 and 4.7 months, respectively (p=.28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.

AB - The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n=48) or FIA (n=33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p=.50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p=.48), and the median overall survival was 6.3 and 4.7 months, respectively (p=.28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.

KW - Acute myeloid leukemia

KW - Clofarabine

KW - Fludarabine

KW - Purine nucleoside analogues

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85024488470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024488470&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1349907

DO - 10.1080/10428194.2017.1349907

M3 - Article

C2 - 28718728

AN - SCOPUS:85024488470

VL - 59

SP - 813

EP - 820

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -